SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMMULOGIC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: aknahow who wrote (58)10/23/1996 9:09:00 PM
From: Rudy Saucillo   of 305
 
Thanks, George, for pointing out the possibility of error from the referenced web site. I checked the institutional holding numbers today in Standard & Poors and they matched. So, I'm reasonably confident that the 78% figure is correct. My point in citing accumulation numbers is that money managers (who, BTW, for the most part are *not* biotech experts) have come to realize that IMUL trades at a substantial discount to projected FY1999 earnings (when Allervax Ragweed and Cat profits start rolling in). IMO, this will cease to be the case after the new Allervax partnership(s) is announced. Although nothing is a sure thing and unexpected adverse events do happen surprisingly often, the risk vs. reward of an IMUL investment has caught the attention of serious money managers. Cheers! Rudy
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News